Valsartan Defendants Can’t Get Plaintiffs’ Funding Agreements

Sept. 19, 2019, 4:09 PM

Drugmakers facing suits alleging generic blood pressure medication was tainted with a probable cancer-causing agent can’t automatically get information about plaintiffs’ litigation funding, a federal court ruled.

Litigation funding is irrelevant to the claims and defenses in the case and, therefore, not discoverable, the U.S. District Court for the District of New Jersey said Sept. 18.

The court is overseeing the multidistrict litigation that stemmed from recalls of generic valsartan, which is used by millions of Americans.

The proceeding includes about 126 individual personal injury suits alleging the drug caused cancer, as well as proposed nationwide class suits seeking medical ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.